Highlights of Tobracef

  • Launched First Time in India, patented in India and South Africa.
  • Tobracef is excellent choice against MDR gram -ve pathogens.
  • Tobracef shows synergistic effect (Acc. to martindale : page :-234) so as to overcome resistant strains of producing pathogens like Pseudomonas , E.coli, K.pneumoniae, Enterobacteriacae etc.
  • Tobracef as a  brand shows reduction in Oxidative stress and lipid peroxidation, so it’s safe to renel tissues as compared to Tobramycin and ceftazidime alone.
  • Tobracef prevents the skin graft failure by inhibiting gram-ve pathogens like Psudomonas aeruginosa, Enterobacteriacae etc. Tobracef is availabe with super solvent which shows following advantages.
  • Tobracef breaks gylcocalyx and enhance drug up take up to 85.3 %.
  • Tobracef works at lower MIC value.
  • Tobracef shows 89 % susceptibility in MDR gram negative pathogens.
  • Clinical success rate of Tobracef is 88.4 %.